Cargando…

Effects of Combined Inorganic Nitrate and Nitrite Supplementation on Cardiorespiratory Fitness and Skeletal Muscle Oxidative Capacity in Type 2 Diabetes: A Pilot Randomized Controlled Trial

Nitric oxide (NO) stimulates mitochondrial biogenesis in skeletal muscle. However, NO metabolism is disrupted in individuals with type 2 diabetes mellitus (T2DM) potentially contributing to their decreased cardiorespiratory fitness (i.e., VO(2)max) and skeletal muscle oxidative capacity. We used a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Kristen D., Kronemberger, Ana, Bae, Dam, Bock, Joshua M., Hughes, William E., Ueda, Kenichi, Feider, Andrew J., Hanada, Satoshi, de Sousa, Luis G. O., Harris, Matthew P., Anderson, Ethan J., Bodine, Sue C., Zimmerman, M. Bridget, Casey, Darren P., Lira, Vitor A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654804/
https://www.ncbi.nlm.nih.gov/pubmed/36364742
http://dx.doi.org/10.3390/nu14214479
Descripción
Sumario:Nitric oxide (NO) stimulates mitochondrial biogenesis in skeletal muscle. However, NO metabolism is disrupted in individuals with type 2 diabetes mellitus (T2DM) potentially contributing to their decreased cardiorespiratory fitness (i.e., VO(2)max) and skeletal muscle oxidative capacity. We used a randomized, double-blind, placebo-controlled, 8-week trial with beetroot juice containing nitrate (NO(3)(−)) and nitrite (NO(2)(−)) (250 mg and 20 mg/day) to test potential benefits on VO(2)max and skeletal muscle oxidative capacity in T2DM. T2DM (N = 36, Age = 59 ± 9 years; BMI = 31.9 ± 5.0 kg/m(2)) and age- and BMI-matched non-diabetic controls (N = 15, Age = 60 ± 9 years; BMI = 29.5 ± 4.6 kg/m(2)) were studied. Mitochondrial respiratory capacity was assessed in muscle biopsies from a subgroup of T2DM and controls (N = 19 and N = 10, respectively). At baseline, T2DM had higher plasma NO(3)(−) (100%; p < 0.001) and lower plasma NO(2)(−) levels (−46.8%; p < 0.0001) than controls. VO(2)max was lower in T2DM (−26.4%; p < 0.001), as was maximal carbohydrate- and fatty acid-supported oxygen consumption in permeabilized muscle fibers (−26.1% and −25.5%, respectively; p < 0.05). NO(3)(−)/NO(2)(−) supplementation increased VO(2)max (5.3%; p < 0.01). Further, circulating NO(2)(−), but not NO(3)(−), positively correlated with VO(2)max after supplementation (R(2)= 0.40; p < 0.05). Within the NO(3)(−)/NO(2)(−) group, 42% of subjects presented improvements in both carbohydrate- and fatty acid-supported oxygen consumption in skeletal muscle (vs. 0% in placebo; p < 0.05). VO(2)max improvements in these individuals tended to be larger than in the rest of the NO(3)(−)/NO(2)(−) group (1.21 ± 0.51 mL/(kg*min) vs. 0.31 ± 0.10 mL/(kg*min); p = 0.09). NO(3)(−)/NO(2)(−) supplementation increases VO(2)max in T2DM individuals and improvements in skeletal muscle oxidative capacity appear to occur in those with more pronounced increases in VO(2)max.